Welcome to our dedicated page for CASTLE BIOSCIENCES SEC filings (Ticker: CSTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CASTLE BIOSCIENCES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CASTLE BIOSCIENCES's regulatory disclosures and financial reporting.
Castle Biosciences Inc. President and Chief Executive Officer Derek J. Maetzold reported open-market sales of 4,172 shares of common stock on July 14, 2026 at a weighted-average price of about $22.92 per share, executed largely through family trusts and related entities.
He also exercised stock options for 550 shares at an exercise price of $2.39 per share. The sales were carried out under a Rule 10b5-1 trading plan adopted on December 3, 2025, and many positions are reported as indirect holdings through various Maetzold family trusts and grantor retained annuity trusts.
Castle Biosciences CEO Derek Maetzold reported option exercises and share sales in Castle Biosciences Inc. common stock. On July 1, 2026, he exercised options for 6,214 shares at $2.39 per share and related entities sold a combined 9,836 shares in open-market transactions at a weighted-average price of $24.29, pursuant to a pre-arranged Rule 10b5-1 plan.
Following these transactions, one direct holding shows 21,479 shares of common stock, and various family and grantor retained annuity trusts associated with Maetzold continue to hold additional indirect positions.
Castle Biosciences Chief Operating Officer Kristen M. Oelschlager reported open-market sales of a total of 8,586 shares of Common Stock on July 1, 2026, executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 17, 2026.
The sales were completed in two weighted-average price transactions: 8,186 shares at $24.40 per share and 400 shares at $24.78 per share, across multiple trades within disclosed price ranges. Following these transactions, she holds 21,874 shares directly and 97,251 shares indirectly through the Fritz Shorter Trust, where she and her spouse serve as trustees and beneficiaries.
Multiple Rule 144 sale notices report transactions by Derek Maetzold and related trusts. The filings list numerous small open-market dispositions of Common shares carried out across April–June 2026 by trusts and entities associated with Maetzold. Examples include sales of 6,214 shares for $155,156.64 and 1,357 shares for $29,981.21 on the dates shown in the excerpt. The entries identify trusts (e.g., The Maetzold 2018 Remainder Trust, The Maetzold Descendants 2020 Trust) and an irrevocable trust as selling holders. Payment amounts are shown per sale line; the filing reports repeated, modest transactions over multiple dates.
CASTLE BIOSCIENCES INC Chief Operating Officer Kristen M. Oelschlager reported an open-market sale of 8,587 shares of common stock at a weighted-average price of $20.71 per share on June 16, 2026. The sale was executed as a planned transaction under a Rule 10b5-1 trading plan adopted on March 17, 2026.
Following this sale, she holds 30,460 shares of common stock directly and 97,251 shares indirectly through The Fritz Shorter Trust, where she and her spouse serve as trustees and beneficiaries.
CASTLE BIOSCIENCES INC director and CEO Derek J. Maetzold reported a mix of option exercises and pre-planned share sales involving his direct and trust-related holdings. He exercised stock options to acquire 550 shares of common stock at $2.39 per share, increasing his direct holdings before selling shares.
Entities associated with him, including several 2018 and 2020 family trusts, sold a combined 4,172 shares of common stock in open-market transactions at a weighted-average price of $20.66 per share. These sales were carried out under a Rule 10b5-1 trading plan adopted on December 3, 2025, indicating the trades were pre-scheduled. Following the transactions, Maetzold holds 21,479 shares directly and various additional indirect positions through multiple grantor retained annuity and remainder trusts.
CSTL filed a Rule 144 notice reporting proposed sales tied to an exercise of stock options. The filing lists 4,152 shares associated with the option exercise dated 06/16/2026 and also shows 25,759 restricted and performance stock units with a 12/31/2025 date.
Castle Biosciences CEO Derek J. Maetzold reported a mix of option exercises and share sales in Castle Biosciences Inc. common stock. He exercised stock options to acquire 6,214 shares at a price of $2.3900 per share and sold 9,836 shares in open-market transactions at a weighted-average price of $20.8570 per share.
Part of the sales came from entities such as The Maetzold Descendants 2020 Trust, the Derek Maetzold 2020 Irrevocable Trust and several 2018 remainder trusts, while a portion was from his direct holdings, which totaled 21,479 shares after these transactions. All sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 3, 2025.
The filing reports multiple Rule 144-related dispositions of common stock by entities and trusts associated with Derek Maetzold, with sizeable blocks sold across March–May 2026. Representative transactions include a sale of 23,179 shares on 03/12/2026 and repeated smaller trust sales; proceeds are shown per trade.
Olson Tiffany reported acquisition or exercise transactions in this Form 4 filing.
Castle Biosciences director Tiffany Olson received a grant of 11,766 Restricted Stock Units as equity compensation. Each RSU represents the right to receive one share of Castle Biosciences common stock at no purchase price.
The RSUs vest in full on the earlier of the one-year anniversary of May 28, 2027, or the day immediately before the company’s next Annual Meeting of Stockholders following the grant date. After this award, Olson holds 11,766 RSUs directly, and the filing shows no additional option or derivative positions.